News
The European Medicines Agency's safety committee has concluded that a potentially dangerous eye condition is a very rare side ...
The European Medicines Agency's (EMA) safety committee (PRAC) has concluded its review of medicines containing semaglutide ...
Novo Nordisk's (NVO) weight loss drug semaglutide (Ozempic, Wegovy, Rybelsus) is linked to a rare eye condition called NAION ...
1d
Zacks.com on MSNIs Novo Nordisk's Next Generation Obesity Pipeline a Game Changer?NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.
Legal battle over semaglutide between Novo Nordisk and Indian drugmakers will set precedent for future opportunities and ...
This is the first time a regulator has confirmed the side effect. Read more at straitstimes.com. Read more at straitstimes.com.
Given the evidence, the committee has recommended that the labels for Novo Nordisk’s Wegovy and Ozempic be updated to include ...
Legal battle over Novo Nordisk's semaglutide drug in India, with DRL, raises concerns over patent infringement and drug ...
Novo Nordisk has filed a lawsuit in Delhi High Court. The suit aims to stop Dr Reddy's Laboratories and OneSource from ...
Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...
Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...
Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results